Marfan syndrome and related connective tissue disorders (Loeys-Dietz + vascular EDS)

What changes during this transition

Marfan syndrome is a heritable connective tissue disorder caused by mutations in FBN1 (chromosome 15q21.1) encoding fibrillin-1, a structural microfibril protein in elastic and non-elastic connective tissue. Loss of normal fibrillin-1 disrupts microfibril assembly AND dysregulates TGF-β signaling — both contribute to the multi-system phenotype. Incidence is roughly 1 in 5,000; about three-quarters of cases are autosomal dominant familial and one-quarter sporadic. Diagnosis follows the revised Ghent nosology (2010), with aortic root dilation and ectopia lentis as major criteria alongside FBN1 mutation and family history. Manifestations span skeletal (tall stature, arachnodactyly, pectus deformity, scoliosis, joint hypermobility, high-arched palate), cardiovascular (aortic root dilation, mitral valve prolapse, arrhythmias), ocular (ectopia lentis, severe myopia, retinal detachment), skin (striae atrae), dural (lumbosacral dural ectasia), and pulmonary (pneumothorax, emphysematous bullae). The load-bearing mortality driver is aortic dissection — the entire cardiovascular surveillance and prevention program is built around that risk. Standard of care is multidisciplinary lifelong management with no curative therapy: cardiology (carrying the aortic surveillance and dissection-prevention load), ophthalmology, orthopedics, cardiothoracic surgery, and medical genetics. Aortic dissection prevention rests on blood pressure and aortic-wall-stress control: beta-blockers (atenolol, metoprolol, propranolol) were the historical first-line, and the 2014 Pediatric Heart Network Marfan trial established losartan as equivalent to atenolol for aortic root growth in children and adolescents — angiotensin-pathway blockade engages TGF-β-related signaling that's pathologically elevated in fibrillinopathy. ACE inhibitors and ARBs have expanded use on the same TGF-β rationale; calcium channel blockers are generally avoided. Stimulants (including ADHD medications) are warned against. Lifestyle modification matters: no isometric or heavy resistance training, no contact sports, aerobic limits set by the individual's cardiology team. Prophylactic aortic root replacement is offered when the root approaches 5.0 cm — earlier with family history of early dissection or in Loeys-Dietz — with valve-sparing root replacement (David procedure) preferred over Bentall composite when feasible. Annual echocardiogram plus cross-sectional CT or MRI surveillance continues for life. Endocarditis prophylaxis applies for high-risk dental procedures. Ophthalmologic surveillance manages ectopia lentis and the high-myopia retinal-detachment risk. Pregnancy is a high-risk window — dissection risk peaks during pregnancy and postpartum; pre-pregnancy aortic root assessment is mandatory, aortic root under 4.0 cm is typically considered safe, over 4.5 cm is a relative contraindication, and maternal-fetal medicine + cardiology + cardiothoracic surgery coordination is non-negotiable. Genetic counseling and family cascade FBN1 testing are part of routine care; 50% offspring transmission means siblings and children need screening. Patient advocacy through The Marfan Foundation and Loeys-Dietz Syndrome Foundation supports the community. Related disorders share the substrate concern with their own twists. Loeys-Dietz syndrome (TGFBR1, TGFBR2, SMAD3, TGFB2, TGFB3) presents with more aggressive aortic disease, earlier dissection at smaller root diameters, arterial tortuosity throughout the vascular tree, skin translucency, bifid uvula, and cleft palate — surgical thresholds are lower and the cardiology team's calculus shifts accordingly. Vascular Ehlers-Danlos syndrome (COL3A1) carries arterial, intestinal, and uterine rupture risk in addition to aortic involvement — the fragility extends beyond the aorta. Homocystinuria can mimic Marfan ophthalmologically (ectopia lentis) but is metabolic, not structural. The differential matters because the management algorithms diverge. Editorial substrate framing: connective tissue diseases with aortic dissection risk are an unusual peptide substrate where community peptides aren't just 'uncharacterized' — they may be sharply concerning through specific mechanisms. The GH-axis peptides (CJC-1295, tesamorelin, ipamorelin) elevate IGF-1, and IGF-1 acts directly on vascular smooth muscle cells, fibroblasts, and aortic media — the exact tissue compartment whose fibrillin-1 microfibril architecture is already compromised and whose lifetime mortality risk is dominated by dissection. The Marfan standard of care has moved toward MORE TGF-β-pathway blockade (losartan, ARBs); community peptides that push growth-axis signaling run in the opposite direction of where the cardiology team is steering. BPC-157 is marketed as a 'tendon and ligament healing' peptide, which translates in CTD contexts to a draw for joint hypermobility and recurrent injury populations — but its pro-angiogenic and matrix-remodeling effects in a patient whose ECM is already structurally abnormal are uncharacterized and potentially counterproductive, and the aortic media is connective tissue too. Pregnancy is the sharpest case across all GH-axis peptides — dissection risk peaks in that window, and IGF-1 elevation compounds an already-loaded substrate. No community peptide engages the angiotensin pathway or TGF-β signaling in the disease-modifying direction; the load-bearing interventions remain blood pressure control, surveillance imaging, surgical timing, and lifestyle modification managed by the multidisciplinary team. Sixty-ninth deliberate non-elevation.